Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Total Neoadjuvant Treatment With Preoperative FLOT/Durvalumab Plus Postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma

NCT07507968 is registered in ClinicalTrials.gov with Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest as lead sponsor.

NCT NCT07507968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07507968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Total Neoadjuvant Treatment With Preoperative FLOT/Durvalumab Plus Postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
February 1, 2030
Enrollment
101 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

esophagogastric adenocarcinoma